Bristol-Myers Squibb Co (BUE:BMY) Cyclically Adjusted Revenue per Share: ARS10,677.95 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:BMY Bristol-Myers Squibb Co BUE:BMY
55 GF Score
Price ARS33,040.00
GF Value ARS28,148.51
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share?

Bristol-Myers Squibb Co BUE:BMY +1.85% 55 Cyclically Adjusted Revenue per Share is ARS10,677.95 as of Mar. 2026. GuruFocus rates BUE:BMY with a GF Score™ of 55/100 and a GF Value™ of ARS28,148.51 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bristol-Myers Squibb Co's adjusted revenue per share for the three months ended in Mar. 2026 was ARS7,847.796. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS10,677.95 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bristol-Myers Squibb Co's average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bristol-Myers Squibb Co was 10.70% per year. The lowest was -1.00% per year. And the median was 4.50% per year.

As of today (2026-07-27), Bristol-Myers Squibb Co's current stock price is ARS33040.00. Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ARS10,677.95. Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio of today is 3.09.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bristol-Myers Squibb Co was 6.89. The lowest was 2.08. And the median was 4.40.


Bristol-Myers Squibb Co  (BUE:BMY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=33040.00/10677.95
=3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bristol-Myers Squibb Co was 6.89. The lowest was 2.08. And the median was 4.40.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Related Terms


Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 987.77 1,853.84 5,779.50 7,772.71 10,787.03

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,870.76 8,351.20 10,774.72 10,787.03 10,677.95

BUE:BMY vs PFE, GILD, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio falls into.


BUE:BMY
55GF Score
Bristol-Myers Squibb Co BUE:BMY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bristol-Myers Squibb Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=7847.796/330.2130*330.2130
=7,847.796

Current CPI (Mar. 2026) = 330.2130.

Bristol-Myers Squibb Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 40.557 241.018 55.566
201609 43.729 241.428 59.810
201612 49.385 241.432 67.545
201703 45.476 243.801 61.594
201706 51.403 244.955 69.294
201709 55.969 246.819 74.880
201712 63.328 246.524 84.826
201803 63.801 249.554 84.422
201806 86.955 251.989 113.948
201809 128.009 252.439 167.447
201812 137.576 251.233 180.826
201903 141.364 254.202 183.634
201906 171.210 256.143 220.720
201909 205.598 256.759 264.416
201912 244.794 256.974 314.562
202003 296.355 258.115 379.134
202006 306.421 257.797 392.496
202009 341.699 260.280 433.508
202012 399.962 260.474 507.047
202103 440.378 264.877 549.004
202106 492.285 271.696 598.312
202109 506.730 274.310 609.999
202112 544.964 278.802 645.455
202203 577.943 287.504 663.797
202206 665.595 296.311 741.748
202209 725.671 296.808 807.343
202212 901.138 296.797 1,002.596
202303 1,059.926 301.836 1,159.575
202306 1,281.751 305.109 1,387.212
202309 1,859.279 307.789 1,994.737
202312 2,037.972 306.746 2,193.883
202403 4,941.306 312.332 5,224.196
202406 5,384.916 314.175 5,659.805
202409 5,565.409 315.301 5,828.622
202412 6,140.601 315.605 6,424.823
202503 5,853.274 319.799 6,043.881
202506 7,147.284 322.561 7,316.836
202509 8,140.082 324.800 8,275.742
202512 8,900.425 324.054 9,069.587
202603 7,847.796 330.213 7,847.796

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ARS10,677.95 mean?
Bristol-Myers Squibb Co (BUE:BMY) has a Cyclically Adjusted Revenue per Share of ARS10,677.95 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share too high?
Bristol-Myers Squibb Co's current Cyclically Adjusted Revenue per Share is ARS10,677.95. Overall, Bristol-Myers Squibb Co has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share compare to PFE and GILD?
Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share of ARS10,677.95 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Cyclically Adjusted Revenue per Share is ARS10,677.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BUE:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS28,148.51, compared to a current price of ARS33,040.00 — trading 17.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ARS10,677.95. Bristol-Myers Squibb Co's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BUE:BMY), the current Cyclically Adjusted Revenue per Share is ARS10,677.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (BUE:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of ARS33,040.00 is trading 17.4% above its estimated GF Value™ of ARS28,148.51. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for BUE:BMY:

  • Cyclically Adjusted Revenue per Share: ARS10,677.95
  • GF Value™: ARS28,148.51 vs. price of ARS33,040.00 (17.4% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the BUE:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
55GF Score

Get the complete analysis for BUE:BMY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS33,040.00
Price
ARS28,148.51
GF Value